Gemphire Therapeutics Inc (NASDAQ:GEMP) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.03 and traded as low as $0.92. Gemphire Therapeutics shares last traded at $0.94, with a volume of 4,629 shares changing hands.
A number of research firms have commented on GEMP. Zacks Investment Research downgraded shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. ValuEngine downgraded shares of Gemphire Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $14.90.
The stock has a market cap of $13.23 million, a P/E ratio of -0.56 and a beta of 3.20.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/4380295/gemphire-therapeutics-nasdaqgemp-stock-passes-below-50-day-moving-average-of-1-03.html.
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy.
Further Reading: What are the reasons investors use put options?
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.